Drugs / D012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04673864 | Jan → Mar 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04035538 | Aug → Nov 2019 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04223895 Background | Feb → Mar 2020 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT05526703 Comparator | Sep 2022 → Oct 2023 | essential hypertension | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673864 ↗ |
| Route | Oral | “R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO” NCT04035538 ↗ |